The effects of type 1 IGF receptor inhibition in a mouse model of diabetic kidney disease

Shraga Segal Department of Microbiology and Immunology, Ben Gurion University of the Negev, Beer Sheva, Israel.
Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society (Impact Factor: 1.41). 08/2011; 21(5):285-91. DOI: 10.1016/j.ghir.2011.07.007
Source: PubMed


We have recently shown increased sensitivity to IGF-I induced signal transduction in kidneys of diabetic mice. Accordingly we investigated the effects of PQ401, a novel diarylurea compound that inhibits IGF1R autophosphorylation in type I diabetes.
Control (C) and Diabetic (D) mice were administered PQ401 (CP, DP) or vehicle (C, D) for 3weeks.
CP animals showed a decrease in renal phosphorylated (p-)AKT and p-IGF1R. However, PQ401 had no effect on diabetic state (hyperglycemia, weight loss) or renal disease parameters (hypertrophy, hyperfiltration and albuminuria). Type IV collagen as well as TGF-β mRNA increased in DP and D compared to C. In the CP group renal hypertrophy with fat accumulation in proximal tubuli and increased renal IGF-I, collagen IV and TGF-β mRNA were seen.
IGF1R inhibition by PQ401 exerted no significant effects on diabetic kidney disease parameters, arguing against a role for IGF-I in the pathogenesis of diabetic kidney disease. However, PQ401 affects normal kidneys, inducing renal hypertrophy as well as collagen and fat accumulation, with increased renal IGF-I mRNA, suggestive of a damage-regeneration process. Therefore, this diarylurea compound is not beneficial in early diabetic kidney disease. Its potential deleterious effects on kidney tissue need to be further investigated.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Total RNA from several adult (6-18-month-old) rabbit tissues was characterized using an oligonucleotide probe derived from the extracellular domain of the nucleotide sequence of the rabbit growth hormone receptor (GH-R) cDNA. Multiple GH-R mRNA species of approximately 4.6, approximately 3.3, 2.1 and approximately 1.4 kb were detected. The major 4.6 kb transcript was detectable in all tissues examined but with quite marked abundance differences. The highest level of expression was observed in liver followed closely by muscle. A qualitative assessment of insulin-like growth factor I (IGF-I) mRNA abundance was made in these same tissues. The data showed that the tissue abundance of GH-R mRNA was not necessarily parallel to that of IGF-I mRNA. The ontogeny of GH-R mRNA was studied in rabbit liver, muscle, heart and kidney. Low levels of GH-R mRNA were detectable in all fetal tissues studied except kidney which showed relatively high levels, suggesting that GH may play an important role in early kidney development. The overall developmental pattern of GH-R mRNA was similar in heart, muscle and liver, being low in fetal and early neonatal (day 3) periods and reaching maximal levels between 2 and 6 months. However, in kidney the pattern contrasted markedly. Relatively high levels of GH-R mRNA were observed in fetal and early neonatal (day 3) kidney with little change throughout development. The developmental pattern of IGF-I gene expression was not necessarily co-ordinately regulated with the ontogenic pattern of GH-R gene expression.(ABSTRACT TRUNCATED AT 250 WORDS)
    Molecular and Cellular Endocrinology 02/1992; 83(1):39-49. DOI:10.1016/0303-7207(92)90193-A · 4.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Many pathological states characterized by muscle atrophy (e.g., sepsis, cachexia, starvation, metabolic acidosis and severe insulinopenia) are associated with an increase in circulating glucocorticoid (GC) levels, suggesting that GC could trigger the muscle atrophy observed in these conditions. GC-induced muscle atrophy results from decreased protein synthesis and increased protein degradation. The inhibitory effect of GCs on protein synthesis is thought to result mainly from the inhibition of the p70 ribosomal S6 protein kinase. The stimulatory effect of GCs on muscle proteolysis results from the activation of two major cellular proteolytic systems: ubiquitin proteasome and lysosomal systems. The decrease in muscle production of insulin-like growth factor I (IGF-I), a muscle anabolic growth factor, could contribute to GC-induced muscle atrophy. By activating the phosphatidylinositol-3-kinase/Akt pathway, IGF-I overrides GC action to stunt muscle atrophy. Evidence also indicates that increased production of myostatin, a catabolic growth factor, could play a critical role in GC-induced muscle atrophy. CONCLUSIONS: Recent progress in understanding the role of growth factors in GC-induced muscle atrophy allows investigation into new therapies to minimize this myopathy.
    Hormone Research 11/2009; 72 Suppl 1(supplement 1):36-41. DOI:10.1159/000229762 · 2.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mechanisms contributing to development of diabetic nephropathy (DN) remain unclear. High ambient glucose level transforms intracellular pathways, promoting stable phenotypic changes in the glomerulus such as mesangial cell hypertrophy, podocyte apoptosis, and matrix expansion. Insulin-like growth factors (IGFs) and the high affinity IGF binding proteins (IGFBPs) exert major effects on cell growth and metabolism. Compared with diabetic patients without microalbuminuria (MA), MA diabetic patients display perturbed GH-IGF-IGFBP homeostasis, including increased circulating IGF-I and IGFBP-3 protease activity, increased excretion of bioactive GH, IGF-I, and IGFBP-3, but decreased circulating IGFBP-3 levels. In diabetic animal models, expression of IGF-I and IGFBP-1 to -4 increases in key renal tissues and glomerular ulrafiltrate. Epithelial, mesangial, and endothelial cells derived from the kidney respond to IGF-I binding with increased protein synthesis, migration, and proliferation. This article reviews classic and emerging concepts for the roles of the GH-IGF-IGFBP axis in the etiopathophysiology, treatment, and prevention of diabetic renal disease. We report IGF-independent actions of IGFBP-3 in the podocyte for the first time.
    Diabetes Research and Clinical Practice 06/2007; 76(2):177-86. DOI:10.1016/j.diabres.2006.09.012 · 2.54 Impact Factor
Show more